Alkermes plc. Total Shareholder Rtn Amt
Alkermes plc. (ALKS) reported Total Shareholder Rtn Amt of $142.53 for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-06.
Financial Statements › Notes
ecd:TotalShareholderRtnAmt · last filed 2026-04-06
| Period end | Total Shareholder Rtn Amt 12 month |
|---|---|
| 2025-12-31 | $142.53 DEF 14A · filed 2026-04-06 |
| 2024-12-31 | $146.50 DEF 14A · filed 2026-04-06 |
| 2023-12-31 | $141.31 DEF 14A · filed 2026-04-06 |
| 2022-12-31 | $130.98 DEF 14A · filed 2026-04-06 |
| 2021-12-31 | $116.59 DEF 14A · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |